Retrospective Cohort Study
Copyright ©The Author(s) 2021.
World J Cardiol. Mar 26, 2021; 13(3): 46-54
Published online Mar 26, 2021. doi: 10.4330/wjc.v13.i3.46
Table 1 Baseline characteristics

Clinic, n (%)
RM, n (%)
n45111
Age at implant (year)63.6 ± 13.064.2 ± 11.5
Male30 (85.7)85 (82.5)
NYHA functional class
I12 (34.3)40 (38.8)
II18 (51.4)52 (50.5)
III5(14.3)11 (10.7)
Cardiac disease category
Coronary artery disease 21 (60.0)54 (52.4)
Non ischaemic dilated cardiomyopathy4 (11.4)15 (14.6)
Primary electrical disease3 (8.6)5 (4.9)
Hypertrophic cardiomyopathy1 (2.9)6 (5.8)
Valvular heart disease1 (2.9)2 (1.9)
Hypertensive1 (2.9)3 (2.9)
Other cardiomyopathy1 (2.9)5 (4.9)
Undetermined2 (5.7)10 (9.7)
None1 (2.9)1 (1.0)
ECG history of
Sustained ventricular tachycardia 7 (20.0)24 (23.3)
Ventricular fibrillation 6 (17.1)19 (18.4)
Torsade de pointes1 (2.9)3 (2.9)
Indication for ICD
Primary 20 (57.1)57 (55.3)
Secondary15 (42.9)46 (44.7)
Implanted device
Single chamber ICD 13 (37.1)27 (26.2)
Dual chamber ICD 19 (54.3)74 (71.8)
CRT-D5 (14.3)23 (22.3)
Type of implant
Original30 (85.7)83 (80.6)
Replacement5 (14.3)20 (19.4)
Drug therapy
Beta-blocker 25 (71.4)69 (70.0)
Digoxin 2 (5.7)12 (11.7)
Amiodarone4 (11.4)8 (7.8)
Manufacturer
Biotronik 11 (31.4)44 (42.7)
Boston scientific/guidant 8 (28.8)0 (0)1
Medtronic 5 (14.3)41 (39.8)
St Jude Medical11 (31.4)18 (17.5)
Table 2 Incidence of appropriate and inappropriate shocks and time to medical assessment

Clinic, n (%)
RM, n (%)
n45111
Reason lost to follow up
Out of area3 (6.7)4 (3.6)
Death7(15.6)4 (3.6)
Number of patients receiving shocks (appropriate)3 (8.6)14 (13.6)
1 shock3 (8.6)9 (8.7)
2-9 shocks06 (5.8)
≥ 1000
Number of patients receiving shocks (inappropriate)4 (11.4)4 (3.9)
1 shock02 (1.9)
2-9 shocks2 (5.7)2 (1.9)
≥ 102 (5.7)0
Causes inappropriate shocks (number of shocks)
AF/flutter18 (42.9)2 (20.0)
SVT14 (33.3)1 (10.0)
T wave over sense01 (10.0)
V lead displacement06 (60.0)
Noise10 (23.8)0
TMA
Appropriate shocks11.7 ± 9.21.8 ± 0.6
Inappropriate shocks15.1 ± 6.81.0 ± 0.0